No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 1 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Attovia Therapeutics, Inc. (ATTO) stock was $17.78 as of Oct 6, 2026, 1:00 PM EDT, down 1.22% from the previous close.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis.
Biotechnology · San Carlos, CA
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-4.88
vs Estimate
$-4.62
Revenue
$450000.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ATTO | $764.86M | $17.77 | -1.22% | N/A | N/A | N/A | N/A |
| 2MLAB | $764.65M | $136.65 | -3.93% | +94.75% | -13.52% | +2.29% | vs ATTO |
| 3SANA | $776.43M | $2.79 | -3.12% | -27.16% | -32.33% | N/A | vs ATTO |
| 4DSGN | $752.61M | $12.05 | -2.98% | +102.59% | -3.82% | N/A | vs ATTO |
| 5LXRX | $777.34M | $1.75 | +0.57% | +23.28% | -18.54% | -21.03% | vs ATTO |
| 6APMD | $785.11M | $19.71 | -9.36% | N/A | N/A | N/A | vs ATTO |
forward FY estimate
N/A
vs Estimate
$316667.00
Consensus Rating
Based on 5 analysts
Average Price Target
$42.20
+137.4% upside
Low
$30.00
Current
$17.77
High
$52.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.56 | $-0.56 | $-0.56 | 1 |
| Quarter ending Dec 2026 | $-0.49 | $-0.49 | $-0.49 | 1 |
| Quarter ending Mar 2027 | $-0.44 | $-0.44 | $-0.44 | 1 |
| Quarter ending Jun 2027 | $-0.44 | $-0.44 | $-0.44 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-4.31 | $-4.06 | $-3.93 | 1 |
| FY 2027 | $-2.53 | $-2.38 | $-2.31 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $450000.00 | $450000.00 | $450000.00 | 1 |
| Quarter ending Dec 2026 | $450000.00 | $450000.00 | $450000.00 | 1 |
| Quarter ending Mar 2027 | $450000.00 | $450000.00 | $450000.00 | 1 |
| Quarter ending Jun 2027 | $450000.00 | $450000.00 | $450000.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $439154.00 | $450000.00 | $471684.00 | 2 |
| FY 2027 | $1.32M | $1.35M | $1.42M | 3 |
